2 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 2, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
Follow Primary Mediastinal Large B-Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal Large B-Cell Lymphoma trials Research Report on Primary Mediastinal Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis LITT + Pembrolizumab - Melanoma, Non-small Cell Lung Carcinoma (NSCLC) | Phase 1 | Terminated | University of Florida | 10 | 2020-01-10 | 2023-12-27 |
| Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs Decitabine, GVD chemotherapy, SHR-1210 - Primary Mediastinal Large B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-05-01 | 2018-12-03 |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 400 | 2013-06-13 | 2024-03-26 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Follicular (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Esophageal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Recurrence (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Lymphoma, B-Cell (4) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Brain Diseases (1)
Cyclophosphamide (2) · Doxorubicin (2) · Prednisone (2) · Rituximab (2) · deltacortene (2) · polatuzumab vedotin (2) · CT-P10 (1) · Decitabine (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1) · Magnetic Resonance Spectroscopy (1) · Methylprednisolone (1) · Prednisolone (1) · Specimen Handling (1) · axicabtagene ciloleucel (1)
Chinese PLA General Hospital (1) · Epizyme, Inc. (1) · Genmab (1) · Jonsson Comprehensive Cancer Center (1) · NeoImmuneTech (1) · University of Florida (1) · University of Washington (1)
United States (6) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Taiwan (1) · Ukraine (1) · United Kingdom (1)
John DiPersio, M.D. (1) · Maryam Rahman, MD (1) · Ryan Lynch (1) · Sven De Vos (1)
PMID 29650362, PMID 33035457, PMID 36521030, PMID 37981564, PMID 39563886, PMID 40802906
2019 (1)